| 12/09/2025 13:00 |
Sumitomo Pharma America Presents New Investigational Data on Enzomenib and Nuvisertib at the ASH 2025 |
| 10/31/2025 15:30 |
Supplementary Financial Data (IFRS) for the Second Quarter of the Year Ending March 31, 2026 |
| 10/31/2025 15:30 |
Presentation Material (Conference on Q2 FY2025 Financial Results) |
| 10/31/2025 15:30 |
Summary of Consolidated Financial Results for the Second Quarter (First Half) of the Year Ending March 31, 2026 [IFRS] |
| 10/31/2025 15:30 |
(Progress of Disclosure Matters) Confirmation of Gain on Sales of Shares of Subsidiaries in connection with the Company Split of Asian Business |
| 10/31/2025 15:30 |
Sumitomo Pharma Announces Variances Between Its Financial Forecasts for the Half-Year Ended September 30, 2025, and Revisions to Financial Forecasts |
| 08/05/2025 11:30 |
Submission of the Application of Manufacturing and Marketing Authorization for iPS Cell-Derived dopaminergic neural progenitor cells in Japan |
| 07/31/2025 15:30 |
Supplementary Financial Data (IFRS) for the First Quarter of the Year Ending March 31, 2026 |
| 07/31/2025 15:30 |
Presentation Material (Conference on Q1 FY2025 Financial Results) |
| 07/31/2025 15:30 |
Notice Concerning Finance Costs |
| 07/31/2025 15:30 |
(Progress of Disclosure Matters) Completion of Procedures for Company Split of Asian Business and Share Transfer to Marubeni Global Pharma |
| 07/31/2025 15:30 |
Summary of Consolidated Financial Results for the First Quarter of the Year Ending March 31, 2026 [IFRS] |
| 07/01/2025 11:20 |
Corporate Governance Report |
| 06/26/2025 17:30 |
Notice of Assignment of Assets for Key Products in the U.S. within Sumitomo Pharma Group |
| 06/26/2025 17:30 |
Matters Concerning Controlling Shareholders, Etc. |
| 05/30/2025 08:00 |
Other Matters Subject to Measures for Electronic Provision for the 205th Annual Shareholders' Meeting (Matters Omitted from the Delivered Documents) |
| 05/30/2025 08:00 |
Notice of Convocation of the 205th Annual Shareholders' Meeting and Meeting Materials |
| 05/28/2025 15:30 |
(Progress of disclosure matters) Notice Regarding a Company Split of the Asian Business and Share Transfer with Marubeni Global Pharma Corporation |
| 05/13/2025 13:00 |
Supplementary Financial Data (IFRS) for the Year Ended March 31, 2025 |
| 05/13/2025 13:00 |
Summary of Consolidated Financial Results for the Year Ended March 31, 2025 [IFRS] |
| 05/13/2025 13:00 |
Presentation Material Conference on FY2024 Financial Results and Reboot 2027 Reboot for a Strong Sumitomo Pharma |
| 05/13/2025 13:00 |
Sumitomo Pharma Announces Reboot 2027 - Reboot for a Strong Sumitomo Pharma - |
| 05/13/2025 13:00 |
Notice Regarding the Estimated Recording of Gain on Transfer of Shares in Affiliated Companies |
| 05/13/2025 13:00 |
Notice of Partial Amendment to the Articles of Incorporation |
| 05/13/2025 13:00 |
Notice Regarding Appointment of Executive and Other Key Personnel |
| 04/28/2025 17:00 |
Sumitomo Pharma Announces Revisions to Its Financial Forecasts and Recording of Gains from Transfer of Equity Interests |
| 04/04/2025 15:30 |
Sumitomo Pharma Announces Reduction in Executive Remuneration |
| 03/28/2025 16:00 |
Notice of Transition to Company with an Audit & Supervisory Committee |
| 03/26/2025 11:30 |
Notice Regarding Refinancing of Existing Borrowings Through a Syndicated Loan |
| 02/28/2025 15:30 |
Notice of Capital Reorganization within Sumitomo Pharma Group |
| 01/31/2025 15:30 |
Summary of Consolidated Financial Results for the Third Quarter of the Year Ending March 31, 2025 [IFRS] |
| 01/31/2025 15:30 |
Conference on Q3 FY2024 (April 1, 2024 to December 31, 2024) Financial Results |
| 01/31/2025 15:30 |
Supplementary Financial Data (IFRS) for the Third Quarter of the Year Ending March 31, 2025 |
| 01/31/2025 15:30 |
Sumitomo Pharma Announces Revisions to Its Financial Forecasts |
| 01/31/2025 15:30 |
Notice Concerning Finance Income |
| 01/20/2025 15:30 |
Sumitomo Pharma Announces Agreement on Co-Promotion Collaboration Partner for Marketing of PPLAT XEPLION and XEPLION TRI in Japan |
